AUTHORS
Costanza Tacchi, PharmD, Gustavo de Oliveira Canedo, MD2, Purushotham Ramachandran3, Subramaniam Ramanathan4, Katherine Clesham, MBBS, FRPATH5, Daniel Angelov, MBBS, MSc, MB6, Aisling Busher7, Nida Shafique8, Macarena Oporto Espuelas9, Gemma Davidson10, Philip Ancliff, FRCPath11, Robert Chiesa, MD12, Arina Lazareva13, David O'Connor, PhD, FRCPath, MBChB14, Vesna Pavasovic15, Kanchan Rao16, Juliana Silva17, Emma Nicholson18, Persis J Amrolia, MD, PhD19, Denise Bonney20, Geoff Shenton, MBChB, FRCPath, FRCPCH, MRCP21, Rachael Hough, MD22, Sara Ghorashian, FRCPath, PhD23
AFFILIATIONS
1 UCL Great Ormond Street Institute of Child Health, London, United Kingdom, University of Pisa, Pisa, Italy
2 UCL Great Ormond Street Institute of Child Health, London, United Kingdom
3 Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
4 Manchester University NHS Foundation Trust, Manchester, United Kingdom
5 University College London Hospitals NHS Foundation Trust, London, United Kingdom
6 Children's Health Ireland, Dublin, Ireland, Dublin, Ireland, Great Ormond Street Hospital, London, United Kingdom
7 Children's Health Ireland, Dublin, Ireland
8 Royal Marsden Hospital, London, United Kingdom
9 UCL Great Ormond Street Institute of Child Health, London, United Kingdom
10 Great Ormond Street Hospital for Children, London, United Kingdom
11 Great Ormond Street Hospital, London, United Kingdom
12 Great Ormond Street Hospital, London, United Kingdom
13 Great Ormond Street Hospital, London, United Kingdom
14 Great Ormond Street Hospital, London, United Kingdom
15 Great Ormond Street Hospital, London, United Kingdom
16 Great Ormond Street Hospital, London, United Kingdom
17 Great Ormond Street Hospital, London, United Kingdom
18 Royal Marsden Hospital, London, United Kingdom
19 UCL Great Ormond Street Institute of Child Health, London, United Kingdom
20 Manchester University NHS Foundation Trust, Manchester, United Kingdom
21 Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
22 University College London Hospitals NHS Foundation Trust, London, United Kingdom
23 UCL Great Ormond Street Institute of Child Health, London, United Kingdom
ABSTRACT
Chimeric antigen receptor T-cell therapy (CART) has significantly changed therapy of children and young adults (CAYA) with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Optimal management for those with early B cell recovery/loss of B cell aplasia (ELBCA, ≤6 months from infusion after tisagenlecleucel) remains uncertain. Here we report a multi-center cohort of CAYA with ELBCA.
We retrospectively collected data from 6 UK/Irish centres for patients (pts) treated between Jan 2019 to Jan 2026 (data cut-off 27 Jul 2026). Inclusion required ELBCA and negative measurable residual disease (MRD, measured by qPCR). LBCA was defined as recovery of peripheral B-cell count ≥0.01 × 10^9/L and/or bone marrow CD19+ events ≥0.1% measured twice >2 weeks apart with rising values. Duration of B-cell aplasia was time from infusion to LBCA or CD19+ relapse. UKALL cytogenetic risk was categorized. Overall survival (OS) was from CART infusion to death (any cause), event-free survival (EFS) was time from infusion to frank relapse (>5% bone marrow blasts). Stringent EFS (sEFS) was time from infusion to relapse, death, or initiation of antileukemic therapy. Pts alive or event-free were censored at last follow-up. Survival analyses used Kaplan-Meier estimates, log-rank comparison.
Median time to peripheral blood B-cell recovery was 78(IQR 51.5-95) days. Most pts were male (n=31, 52.5%), median age was 9.2(IQR 6.1-13.1) years. Cytogenetic risk was good in 23(39%) pts, intermediate in 12(20.3%), and poor in 18(30.5%) pts. CART indications were primary refractory disease (n=2, 3.4%), refractory relapse (n=18, 30.5%), ≥ 2 relapses (n=9, 15.3%), relapse post hematopoietic stem cell transplantation (HSCT) (n=8, 13.6%), or inability to proceed to recommended HSCT (n=18, 30.5%).
Treatments for ELBCA were maintenance, HSCT, repeat CART, other therapies or none. Of 59 pts included, 22(37.3%) received maintenance therapy and 28(47.5%) HSCT. There was no difference (p=0.75) in median time to B-cell recovery between these cohorts.
No therapy was given in 2(3.4%) pts after ELBCA. A further 2(3.4%) pts received repeat CART infusion for ELBCA, one for CD19+ frank relapse at 4 months (mo) after the first infusion and family preference in the other. Other therapies, given in 5(8.5%) cases included blinatumomab plus maintenance.
Median follow-up was 24.2mo (95%CI 20-37.5) for the whole cohort with no difference between sub-groups (p=0.09). Median OS, EFS and sEFS for the whole cohort were not reached (NR). Estimated OS at 12mo was 92.3%(95%CI 85.4-99.9) and 86.7%(77-97.6) at 24mo. Estimated EFS at 12mo was 91%(83.7-98.9) and 85.4%(75.6-96.4) at 24mo. Estimated sEFS at 12mo was 81.9%(72.3-92.8) and 74.2%(62.7-87.7) at 24mo.
There was no significant difference in OS, EFS and sEFS between maintenance and HSCT groups (p=0.55, 0.48 and 0.5 respectively, median survival NR).
At 12mo OS was 90%(77.8-100) for maintenance and 92%(82-100) for HSCT groups (p=0.84). At 24mo OS was 90%(77.8-100) and 86.9%(74-100) respectively (p=0.83). At 12mo EFS was 90.2%(78.2-100) and 87.8%(75.8-100) respectively (p=0.83). At 24mo EFS was 82.7%(66.2-100) and 82.7%(68.4-99.9) respectively (p=0.92). At 12mo sEFS was 90.5%(78.8-100) and 88%(76.1-100) respectively (p=0.79). At 24mo sEFS was 82.9%(66.6-100) and 82.8%(68.6-100) respectively (p=0.99).
Of 22 maintenance pts, 2 subsequently had HSCT, one for emergence of MRD at 5mo, one for CD19+ frank relapse after 1 year from maintenance. Another 2 pts had CD19+ frank relapse by 2mo and after 2 years from maintenance respectively. Of 28 HSCT pts, 3 relapsed within 1mo (CD19+), at 3mo and after 2 years post-HSCT. At last follow-up, 50(84.7%) pts were alive in molecular remission, 1(1.7%) alive with disease, 6(10.2%) died of disease and 2(3.4%) died in remission (TRM post-HSCT). No TRM occurred with maintenance.
Maintenance chemotherapy provided outcomes comparable to HSCT, suggesting it may be a valid alternative for pts with ELBCA following tisagenlecleucel. Previous studies reflect heterogeneity in B-cell aplasia duration after CD19-directed CART, reflecting differences in persistence, product characteristics, and patient factors. Our findings are comparable to our previous pilot study (Gabelli et al., Blood Adv 2024) and support prospective investigation of maintenance chemotherapy for ELBCA post CART. Limitations include retrospective design, limited cohort size and follow-up. We will report updated outcomes at the meeting.
DISCLOSURES
Sara Ghorashian, FRCPath, PhD: Autolus - Consultancy (Includes expert testimony)